Prelude Therapeutics (PRLD) Expected to Announce Earnings on Tuesday

Prelude Therapeutics (NASDAQ:PRLDGet Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect Prelude Therapeutics to post earnings of ($0.48) per share for the quarter.

Prelude Therapeutics (NASDAQ:PRLDGet Free Report) last released its earnings results on Monday, March 10th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.11. The firm had revenue of $4.00 million during the quarter. On average, analysts expect Prelude Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Prelude Therapeutics Stock Down 3.4 %

Shares of PRLD opened at $0.89 on Friday. The stock’s fifty day simple moving average is $0.75 and its 200-day simple moving average is $1.00. The firm has a market capitalization of $50.10 million, a PE ratio of -0.50 and a beta of 1.35. Prelude Therapeutics has a 12-month low of $0.61 and a 12-month high of $6.80.

Insider Buying and Selling at Prelude Therapeutics

In related news, CEO Krishna Vaddi purchased 47,500 shares of the stock in a transaction dated Wednesday, March 12th. The stock was bought at an average cost of $0.71 per share, with a total value of $33,725.00. Following the purchase, the chief executive officer now directly owns 1,214,775 shares in the company, valued at $862,490.25. The trade was a 4.07 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, insider Andrew Combs acquired 100,000 shares of Prelude Therapeutics stock in a transaction that occurred on Tuesday, March 25th. The shares were purchased at an average cost of $0.69 per share, for a total transaction of $69,000.00. Following the purchase, the insider now directly owns 480,123 shares in the company, valued at $331,284.87. The trade was a 26.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 822,500 shares of company stock valued at $568,475. 62.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PRLD shares. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Prelude Therapeutics in a research report on Tuesday, April 8th. JMP Securities restated a “market outperform” rating and issued a $4.00 price objective on shares of Prelude Therapeutics in a report on Tuesday, April 29th.

Check Out Our Latest Stock Analysis on Prelude Therapeutics

Prelude Therapeutics Company Profile

(Get Free Report)

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.

Read More

Earnings History for Prelude Therapeutics (NASDAQ:PRLD)

Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.